Keyphrases
Malignant Pleural Mesothelioma
100%
Immune Therapy
100%
Checkpoint Blockade
100%
Overall Survival
40%
Mesothelin
20%
T Cells
20%
Malignancy
20%
Antitumor Activity
20%
Targeted Therapy
20%
Ipilimumab
20%
Conventional Chemotherapy
20%
Nivolumab
20%
Immunotherapeutics
20%
Cancer Cells
20%
Orphan Disease
20%
First-line Therapy
20%
Immune Cells
20%
Asbestos Exposure
20%
Immune Checkpoint
20%
Knowledge Gaps
20%
Novel Immunotherapy
20%
Early Phase Clinical Trials
20%
FDA-approved Drugs
20%
Anti-PD-1
20%
Immunogenic
20%
Human Biology
20%
Biological Products
20%
Resectable Disease
20%
Multiple Trials
20%
Malignancy-associated
20%
CTLA-4 Inhibitors
20%
Checkpoint Inhibitor Immunotherapy
20%
Immunotherapy Agents
20%
Medicine and Dentistry
Pleura Mesothelioma
100%
Immunotherapy
100%
Diseases
60%
Cancer
40%
Overall Survival
40%
T Cell
20%
Clinical Trial
20%
Cancer Cell
20%
Targeted Therapy
20%
Mesothelin
20%
Immunocompetent Cell
20%
Nivolumab
20%
Antineoplastic Activity
20%
Biological Molecule
20%
Orphan
20%
Asbestos Exposure
20%
Cytotoxic T Lymphocyte Antigen 4 Antibody
20%
Ipilimumab
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pleura Mesothelioma
100%
Immunotherapy
100%
Diseases
60%
Overall Survival
40%
Clinical Trial
20%
Chemotherapy
20%
Antitumor Activity
20%
Malignant Neoplasm
20%
Mesothelin
20%
Nivolumab
20%
Biological Target
20%
Cytotoxic T Lymphocyte Antigen 4 Antibody
20%
Ipilimumab
20%